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During cancer invasion, breakdown of the extracellular matrix is
accomplished by the concerted action of several proteases,
including the serine protease plasmin and a number of matrix
metalloproteases (MMPs). The activity of each of these proteases
is regulated by an array of activators, inhibitors and cellular
receptors. Thus, the generation of plasmin involves the pro-
enzyme plasminogen, the urokinase type plasminogen activator
uPA and its pro-enzyme pro-uPA, the uPA inhibitor PAI-1, the cell
surface uPA receptor uPAR, and the plasmin inhibitor a2-antiplas-
min. The plasminogen activation system appears to be active in
virtually all types of cancer, while various MMPs appear to be
active more selectively in different types of cancer.
Generation of extracellular proteolysis in cancer involves a
complex interplay between cancer cells and non-malignant stro-
mal cells which has far-reaching consequences for our under-
standing of both carcinogenesis and establishment of
metastases. For some types of cancer, the cellular interplay mim-
ics that observed in the tissue of origin during non-neoplastic tis-
sue remodelling processes. We propose that cancer invasion is
considered as uncontrolled tissue remodelling.
Inhibition of extracellular proteases is an attractive approach
to cancer therapy. Because the proteases have many functions
in the normal organism, efficient inhibition will have toxic side
effects. In cancer invasion, like in normal tissue remodelling
processes, there appears to be a functional overlap between dif-
ferent extracellular proteases. This redundancy means that
combinations of protease inhibitors must be used. Such combi-
nation therapy, however, is also likely to increase toxicity.
Therefore for each type of cancer, a combination of protease
inhibitors that is optimised with respect to both maximal ther-
apeutic effect and minimal toxic side effects needs to be
identified.
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uPAR is a GPI-anchored protein that signals by interacting with
extracellular matrix proteins, transmembrane tyrosine kinase
receptors, integrins and G-protein coupled receptors. uPAR regu-
lates adhesion by either direct RGD-independent binding to vitro-
nectin (VN), or by forming complexes with integrins. In this case
uPAR appears to have higher affinity for alpha5 > alpha3 >
alpham. uPAR can both activate and inactivate integrins and
induce signaling via integrins or via other receptors. A seven
trans-membrane G-protein coupled receptor, FPRL1, directly
interacts with a uPA-cleaved form of uPAR (which cannot bind
integrins) and transmits a chemokine-like signal inducing che-
motaxis. In addition, uPAR can also interact with the EGF-receptor
and induce either cell proliferation (via the ERK pathway) or cell
migration. The choice between these two effects of uPAR may
be dependent on different conformations of uPAR and hence on
different types of interactions in different cells.
An important novel feature of uPAR is its involvement in the
mobilization of hematopoietic stem cells. Indeed, uPAR Ko mice
do not mobilize HSC, but this property can be rescued by admin-
istering a soluble form of uPAR or one of its fragments, D2D3. We
have set up the tools and methodology for measuring the forma-
tion and the level of circulating D2D3 in human biological fluids
since HSC mobilization is an important aspect of leukemia and
lymphoma therapy. Indeed, the availability of a specific D2D3
assay allows the determination of the level of this fragments in
all types of cancer and hence the correlation with the stage of
the tumor.
Overexpression is one of the mechanisms transforming pro-
tooncogenes into oncogenes. In human tumors uPAR is almost
invariably overexpressed. UPAR overexpression controls cell pro-
liferation by constitutively activating integrins and growth factor
receptor pathways. However, recent data on cells carrying no
oncogenes mutation (embryonic mouse fibroblasts, MEF) have
shown that the absence of uPAR causes an increase in cell prolif-
eration rate and delays culture-induced senescence. On the other
hand, overexpression of uPAR in MEFs causes senescence. In this
type of activity, key regulatory proteins of the p53/Rb pathways
are involved.
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Most patients with inoperable primary cancer, with or without
overt metastases, or patients with undetected disseminated dis-
ease undergoing surgery for their primary cancer, are not cured
by adjuvant chemotherapy. It is thought that residual tumor
cells in patients with disseminated disease might exit prolifera-
tion and activate a survival and G0/G1 arrest that allows them to
become dormant. The mechanisms that trigger and maintain
dormancy are not well understood and the assumption that
the lack of proliferation of dormant cells is the only reason
for their resistance to chemotherapy remains to be proven.
The elucidation of the molecular basis of dormancy is of funda-
mental interest. We have shown that a rapidly tumorigenic and
spontaneously metastasizing human carcinoma (T-HEp3) that is
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